These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30660699)

  • 1. Relaxin and extracellular matrix remodeling: Mechanisms and signaling pathways.
    Ng HH; Shen M; Samuel CS; Schlossmann J; Bennett RG
    Mol Cell Endocrinol; 2019 May; 487():59-65. PubMed ID: 30660699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relaxin in hepatic fibrosis: What is known and where to head?
    Ezhilarasan D
    Biochimie; 2021 Aug; 187():144-151. PubMed ID: 34102254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Recombinant Relaxin (Serelaxin) as Anti-fibrotic Agent: Pharmacology, Limitations and Actual Perspectives.
    Sassoli C; Nistri S; Chellini F; Bani D
    Curr Mol Med; 2022; 22(3):196-208. PubMed ID: 33687895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity.
    Pini A; Shemesh R; Samuel CS; Bathgate RA; Zauberman A; Hermesh C; Wool A; Bani D; Rotman G
    J Pharmacol Exp Ther; 2010 Dec; 335(3):589-99. PubMed ID: 20826567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
    Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
    Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relaxin and fibrosis: Emerging targets, challenges, and future directions.
    Kanai AJ; Konieczko EM; Bennett RG; Samuel CS; Royce SG
    Mol Cell Endocrinol; 2019 May; 487():66-74. PubMed ID: 30772373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2.
    Mookerjee I; Hewitson TD; Halls ML; Summers RJ; Mathai ML; Bathgate RA; Tregear GW; Samuel CS
    FASEB J; 2009 Apr; 23(4):1219-29. PubMed ID: 19073841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
    Sandner P; Berger P; Zenzmaier C
    Gerontology; 2017; 63(3):216-227. PubMed ID: 27784018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of relaxin on extracellular matrix remodeling in health and fibrotic disease.
    Samuel CS; Lekgabe ED; Mookerjee I
    Adv Exp Med Biol; 2007; 612():88-103. PubMed ID: 18161483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding relaxin signalling at the cellular level.
    Valkovic AL; Bathgate RA; Samuel CS; Kocan M
    Mol Cell Endocrinol; 2019 May; 487():24-33. PubMed ID: 30592984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease.
    Kramann R; DiRocco DP; Humphreys BD
    J Pathol; 2013 Nov; 231(3):273-89. PubMed ID: 24006178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments on skin fibrosis - Essential signals emanating from the extracellular matrix for the control of myofibroblasts.
    Schulz JN; Plomann M; Sengle G; Gullberg D; Krieg T; Eckes B
    Matrix Biol; 2018 Aug; 68-69():522-532. PubMed ID: 29408278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneously Targeting Myofibroblast Contractility and Extracellular Matrix Cross-Linking as a Therapeutic Concept in Airway Fibrosis.
    Lin YC; Sung YK; Jiang X; Peters-Golden M; Nicolls MR
    Am J Transplant; 2017 May; 17(5):1229-1241. PubMed ID: 27804215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioprotective actions of relaxin.
    Martin B; Romero G; Salama G
    Mol Cell Endocrinol; 2019 May; 487():45-53. PubMed ID: 30625345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redox signaling as a therapeutic target to inhibit myofibroblast activation in degenerative fibrotic disease.
    Sampson N; Berger P; Zenzmaier C
    Biomed Res Int; 2014; 2014():131737. PubMed ID: 24701562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway.
    Heeg MH; Koziolek MJ; Vasko R; Schaefer L; Sharma K; Müller GA; Strutz F
    Kidney Int; 2005 Jul; 68(1):96-109. PubMed ID: 15954899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases.
    Pardali E; Sanchez-Duffhues G; Gomez-Puerto MC; Ten Dijke P
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29039786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directions.
    Samuel CS; Bennett RG
    Biochem Pharmacol; 2022 Mar; 197():114884. PubMed ID: 34968489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Fibrotic Diseases: Current Challenges in Fibrosis Research.
    Rosenbloom J; Macarak E; Piera-Velazquez S; Jimenez SA
    Methods Mol Biol; 2017; 1627():1-23. PubMed ID: 28836191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tensin 1 Is Essential for Myofibroblast Differentiation and Extracellular Matrix Formation.
    Bernau K; Torr EE; Evans MD; Aoki JK; Ngam CR; Sandbo N
    Am J Respir Cell Mol Biol; 2017 Apr; 56(4):465-476. PubMed ID: 28005397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.